Who
Mikael Dolsten
Director
Company insider
Files Form 4 as: Director, Agilent Technologies; Director, Rocket Pharmaceuticals; Director, Apellis Pharmaceuticals; President R&D, Pfizer; Director, Karyopharm Therapeutics; Sr. VP & Pres., Wyeth Research, Wyeth.
In numbers
- Trades disclosed
- 280
- Buys
- 0
- Sells
- 18
- Bought
- $0
- Sold
- $32.1M
- Companies
- 6
- Companies where not an officer
- 4
- First trade
- 16 Jun 2008
- Last trade
- 4 Sep 2026
- Last filed
- 9 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 4 Sep 2026filed 9 Sep 2026 | A Agilent TechnologiesLife-science tools | SEC FORM 4 Sold | $96K634 at $151.38 | filing |
| 4 Sep 2026filed 9 Sep 2026 | A Agilent TechnologiesLife-science tools | SEC FORM 4 Sold | $96K634 at $151.38 | filing |
| 18 Jun 2026filed 6 Jul 2026 | RCKT Rocket PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —22,862 at $0.00 | filing |
| 18 Jun 2026filed 6 Jul 2026 | RCKT Rocket Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —64,860 at $0.00 | filing |
| 18 Jun 2026filed 6 Jul 2026 | RCKT Rocket Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —64,860 at $0.00 | filing |
| 18 Jun 2026filed 6 Jul 2026 | RCKT Rocket PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —22,862 at $0.00 | filing |
| 29 May 2026filed 2 Jun 2026 | A Agilent TechnologiesLife-science tools | SEC FORM 4 Sold | $217K1,600 at $135.42 | filing |
| 29 May 2026filed 2 Jun 2026 | A Agilent TechnologiesLife-science tools | SEC FORM 4 Sold | $217K1,600 at $135.42 | filing |
| 14 May 2026filed 14 May 2026 | Apellis PharmaceuticalsBiotechnology | SEC FORM 4 Code U | —14,312 | filing |
| 14 May 2026filed 14 May 2026 | Apellis PharmaceuticalsBiotechnology | SEC FORM 4 Code D | —14,312 | filing |
| 14 May 2026filed 14 May 2026 | Apellis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —24,135 | filing |
| 14 May 2026filed 14 May 2026 | Apellis Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —24,135 | filing |
| 14 May 2026filed 14 May 2026 | Apellis Pharmaceuticals | SEC FORM 4 Code U | —14,312 | filing |
| 14 May 2026filed 14 May 2026 | Apellis Pharmaceuticals | SEC FORM 4 Code D | —14,312 | filing |
| 19 Mar 2026filed 23 Mar 2026 | A Agilent TechnologiesLife-science tools | SEC FORM 4 Code A | $241K2,158 at $111.75 | filing |
| 19 Mar 2026filed 23 Mar 2026 | A Agilent TechnologiesLife-science tools | SEC FORM 4 Code A | $241K2,158 at $111.75 | filing |
| 27 Feb 2026filed 3 Mar 2026 | Apellis PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —14,312 at $0.00 | filing |
| 27 Feb 2026filed 3 Mar 2026 | Apellis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | $506K24,135 at $20.96 | filing |
| 27 Feb 2026filed 3 Mar 2026 | Apellis Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | $506K24,135 at $20.96 | filing |
| 27 Feb 2026filed 3 Mar 2026 | Apellis Pharmaceuticals | SEC FORM 4 Code A | —14,312 at $0.00 | filing |
News
Maxion Therapeutics Appoints Biopharma Leader Mikael Dolsten to Board of Directorsmanilatimes.net · 20 Oct 2026Agilent Technologies (NYSE:A) Price Target Raised to $196.00A · tickerreport.com · 16 Oct 2026Tech M&A deals: Datacor, MySep, Agilent Technologies, Proscia, Payward, Saldo Bank, Neara, ZepbenA · infotechlead.com · 15 Oct 2026Analyzing Agilent Technologies (NYSE:A) and Qiagen (NYSE:QGEN)A · tickerreport.com · 15 Oct 2026
1 headline in the last 90 days name Mikael Dolsten; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.